Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.
Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.
复制标题
严重的Covid-19患者急性呼吸窘迫综合征患者的康复血浆疗法的功效和安全性。
DOI：
10.1016/j.intimp.2020.107239
复制
发表时间：
2021-04
影响因子：
5.6
通讯作者：
Saeedian N
中科院分区：
文献类型：
--
作者：
Allahyari A;Seddigh-Shamsi M;Mahmoudi M;Amel Jamehdar S;Amini M;Mozdourian M;Javidarabshahi Z;Eslami Hasan Abadi S;Amini S;Sedaghat A;Emadzadeh M;Moeini Nodeh M;Rahimi H;Bari A;Mozaheb Z;Kamandi M;Ataei Azimi S;Abrishami M;Akbarian A;Ataei P;Allahyari N;Hasanzadeh S;Saeedian N
由于SARS-CoV-2感染正在世界各地迅速蔓延，影响到许多人并耗尽卫生保健资源，因此必须迅速研究治疗方案，以开发安全有效的治疗方法。本研究旨在评价恢复期血浆（CP）治疗重症COVID-19合并急性呼吸窘迫综合征（ARDS）的安全性和有效性。本研究64例重症COVID-19合并ARDS确诊病例中，除一线治疗外，32例患者接受了CP治疗。评估他们的临床反应和疾病严重程度和死亡率的结果，并与对照组的其他32名患者进行比较，这些患者是历史匹配的，是随机选择的，除了接受CP治疗外，其他情况相同的患者。采用SPSS软件对数据进行分析。血浆治疗患者的临床结果有所改善，包括SOFA和APACHE II评分的疾病严重程度降低，ICU住院时间缩短，无创通气和插管需求减少，氧合也有所增加。他们还显示死亡率的降低，这在轻度或中度急性呼吸窘迫综合征的不太严重的病例中具有统计学意义。早期给予恢复期血浆可成功治疗有进展至危重状态风险的重症COVID-19伴轻、中度ARDS患者。
Since SARS-CoV-2 infection is rapidly spreading all around the world, affecting many people and exhausting health care resources, therapeutic options must be quickly investigated in order to develop a safe and effective treatment. The present study was designed to evaluate the safety and efficacy of convalescent plasma (CP) for treating severe cases of COVID-19 who developed acute respiratory distress syndrome (ARDS). Among 64 confirmed cases of severe COVID-19 with ARDS in this study, 32 patients received CP besides first line treatment. Their clinical response and outcome in regard to disease severity and mortality rate were evaluated and compared with the other 32 patients in the control group who were historically matched while randomly chosen from previous patients with the same conditions except for receiving CP therapy. Analysis of the data was performed using SPSS software. Patients with plasma therapy showed improvements in their clinical outcomes including a reduction in disease severity in terms of SOFA and APACHE II scores, the length of ICU stay, need for noninvasive ventilation and intubation and also showed an increase in oxygenation. They also showed reduction in mortality which was statistically significant in less severe cases with mild or moderate ARDS. Early administration of the convalescent plasma could successfully contribute to the treatment of severe COVID-19 patients with mild or moderate ARDS at risk of progressing to critical state.
登录
查看更多内容
DOI：
10.1016/s0140-6736(03)13967-0
发表时间：
2003-07-26
期刊：
Lancet (London, England)
影响因子：
--
作者：
Kuiken T;Fouchier RA;Schutten M;Rimmelzwaan GF;van Amerongen G;van Riel D;Laman JD;de Jong T;van Doornum G;Lim W;Ling AE;Chan PK;Tam JS;Zambon MC;Gopal R;Drosten C;van der Werf S;Escriou N;Manuguerra JC;Stöhr K;Peiris JS;Osterhaus AD
通讯作者：
Osterhaus AD
影响因子：
12.8
作者：
Rojas, Manuel;Monsalve, Diana M.;Anaya, Juan-Manuel
通讯作者：
Anaya, Juan-Manuel
使用恢复期血浆治疗 5 名 COVID-19 危重患者。
影响因子：
120.7
作者：
Shen, Chenguang;Wang, Zhaoqin;Liu, Lei
通讯作者：
Liu, Lei
影响因子：
11.8
作者：
Kraft, Colleen S.;Hewlett, Angela L.;Ribner, Bruce S.
通讯作者：
Ribner, Bruce S.
影响因子：
158.5
作者：
Guan, W.;Ni, Z.;Zhong, N.
通讯作者：
Zhong, N.